The company has secured CHF 1M from the UZH Life Sciences Fund to advance its lead candidate through preclinical development.
Founders
Michal Shoshan
Company Description
metaLead Therapeutics is developing a new class of metal-binding drugs aimed at overcoming the shortcomings of existing chelation therapies, focusing on Wilson disease, a genetic disorder that leads to toxic copper accumulation.